EP2323683A1 - Novel use of bacteriocin derived from enterococcus faecalis sl-5 - Google Patents
Novel use of bacteriocin derived from enterococcus faecalis sl-5Info
- Publication number
- EP2323683A1 EP2323683A1 EP08793616A EP08793616A EP2323683A1 EP 2323683 A1 EP2323683 A1 EP 2323683A1 EP 08793616 A EP08793616 A EP 08793616A EP 08793616 A EP08793616 A EP 08793616A EP 2323683 A1 EP2323683 A1 EP 2323683A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- seq
- polypeptide
- acne
- amino acid
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 241000194032 Enterococcus faecalis Species 0.000 title abstract description 22
- 229940032049 enterococcus faecalis Drugs 0.000 title abstract description 21
- 108010062877 Bacteriocins Proteins 0.000 title abstract description 17
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 57
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 56
- 229920001184 polypeptide Polymers 0.000 claims abstract description 54
- 208000002874 Acne Vulgaris Diseases 0.000 claims abstract description 35
- 241000186427 Cutibacterium acnes Species 0.000 claims abstract description 35
- 206010000496 acne Diseases 0.000 claims abstract description 35
- 229940055019 propionibacterium acne Drugs 0.000 claims abstract description 34
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims abstract description 31
- 239000000203 mixture Substances 0.000 claims abstract description 26
- 238000000034 method Methods 0.000 claims abstract description 20
- 238000004519 manufacturing process Methods 0.000 claims abstract description 8
- 239000003242 anti bacterial agent Substances 0.000 claims description 11
- 230000003115 biocidal effect Effects 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 239000002537 cosmetic Substances 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 7
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 34
- 230000001939 inductive effect Effects 0.000 abstract description 8
- 150000001413 amino acids Chemical group 0.000 description 19
- 108090000623 proteins and genes Proteins 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 15
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 12
- 241000894006 Bacteria Species 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 108091028043 Nucleic acid sequence Proteins 0.000 description 7
- -1 for example Substances 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 239000003995 emulsifying agent Substances 0.000 description 6
- 235000014655 lactic acid Nutrition 0.000 description 6
- 239000004310 lactic acid Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- CTBBEXWJRAPJIZ-VHPBLNRZSA-N (1S,2S,3S,6R,8R,9S,10R)-2-benzoyl-1,3,8,10-tetrahydroxy-9-(4-methoxy-6-oxopyran-2-yl)-5-oxatricyclo[4.3.1.03,8]decan-4-one Chemical compound O1C(=O)C=C(OC)C=C1[C@H]1[C@]([C@@H]2O)(O)[C@H](C(=O)C=3C=CC=CC=3)[C@@]3(O)C(=O)O[C@@H]2C[C@]31O CTBBEXWJRAPJIZ-VHPBLNRZSA-N 0.000 description 5
- CTBBEXWJRAPJIZ-UHFFFAOYSA-N Enterocin Natural products O1C(=O)C=C(OC)C=C1C1C(C2O)(O)C(C(=O)C=3C=CC=CC=3)C3(O)C(=O)OC2CC31O CTBBEXWJRAPJIZ-UHFFFAOYSA-N 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000012228 culture supernatant Substances 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 238000001228 spectrum Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000193755 Bacillus cereus Species 0.000 description 3
- 244000063299 Bacillus subtilis Species 0.000 description 3
- 235000014469 Bacillus subtilis Nutrition 0.000 description 3
- 108700026244 Open Reading Frames Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- GEWHMNRKXIVZJF-UHFFFAOYSA-N enterocin l50 Chemical compound Cl.C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C(C(F)(F)F)=C1 GEWHMNRKXIVZJF-UHFFFAOYSA-N 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 229940093915 gynecological organic acid Drugs 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 239000006872 mrs medium Substances 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 235000005985 organic acids Nutrition 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 239000004342 Benzoyl peroxide Substances 0.000 description 2
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 2
- 108010076876 Keratins Proteins 0.000 description 2
- 102000011782 Keratins Human genes 0.000 description 2
- 241000186779 Listeria monocytogenes Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 108010053775 Nisin Proteins 0.000 description 2
- NVNLLIYOARQCIX-MSHCCFNRSA-N Nisin Chemical compound N1C(=O)[C@@H](CC(C)C)NC(=O)C(=C)NC(=O)[C@@H]([C@H](C)CC)NC(=O)[C@@H](NC(=O)C(=C/C)/NC(=O)[C@H](N)[C@H](C)CC)CSC[C@@H]1C(=O)N[C@@H]1C(=O)N2CCC[C@@H]2C(=O)NCC(=O)N[C@@H](C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(NCC(=O)N[C@H](C)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCSC)C(=O)NCC(=O)N[C@H](CS[C@@H]2C)C(=O)N[C@H](CC(N)=O)C(=O)N[C@H](CCSC)C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(N[C@H](C)C(=O)N[C@@H]3C(=O)N[C@@H](C(N[C@H](CC=4NC=NC=4)C(=O)N[C@H](CS[C@@H]3C)C(=O)N[C@H](CO)C(=O)N[C@H]([C@H](C)CC)C(=O)N[C@H](CC=3NC=NC=3)C(=O)N[C@H](C(C)C)C(=O)NC(=C)C(=O)N[C@H](CCCCN)C(O)=O)=O)CS[C@@H]2C)=O)=O)CS[C@@H]1C NVNLLIYOARQCIX-MSHCCFNRSA-N 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 241000531795 Salmonella enterica subsp. enterica serovar Paratyphi A Species 0.000 description 2
- 241000607762 Shigella flexneri Species 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 235000013871 bee wax Nutrition 0.000 description 2
- 239000012166 beeswax Substances 0.000 description 2
- 229960003328 benzoyl peroxide Drugs 0.000 description 2
- 235000019400 benzoyl peroxide Nutrition 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 150000002191 fatty alcohols Chemical class 0.000 description 2
- 235000021107 fermented food Nutrition 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 235000021472 generally recognized as safe Nutrition 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 229960005280 isotretinoin Drugs 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000004309 nisin Substances 0.000 description 2
- 235000010297 nisin Nutrition 0.000 description 2
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 229930002330 retinoic acid Natural products 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 229960001727 tretinoin Drugs 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- RNIADBXQDMCFEN-IWVLMIASSA-N (4s,4ar,5s,5ar,12ar)-7-chloro-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methylidene-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C=C1C2=C(Cl)C=CC(O)=C2C(O)=C2[C@@H]1[C@H](O)[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O RNIADBXQDMCFEN-IWVLMIASSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 1
- ARIWANIATODDMH-AWEZNQCLSA-N 1-lauroyl-sn-glycerol Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)CO ARIWANIATODDMH-AWEZNQCLSA-N 0.000 description 1
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 1
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- KMZHZAAOEWVPSE-UHFFFAOYSA-N 2,3-dihydroxypropyl acetate Chemical compound CC(=O)OCC(O)CO KMZHZAAOEWVPSE-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical group OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 241000237074 Centris Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241001112695 Clostridiales Species 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101000636168 Grapevine leafroll-associated virus 3 (isolate United States/NY1) Movement protein p5 Proteins 0.000 description 1
- 229920000569 Gum karaya Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- IFQSXNOEEPCSLW-DKWTVANSSA-N L-cysteine hydrochloride Chemical compound Cl.SC[C@H](N)C(O)=O IFQSXNOEEPCSLW-DKWTVANSSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- ARIWANIATODDMH-UHFFFAOYSA-N Lauric acid monoglyceride Natural products CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 206010043275 Teratogenicity Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 239000007997 Tricine buffer Substances 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- IJCWFDPJFXGQBN-RYNSOKOISA-N [(2R)-2-[(2R,3R,4S)-4-hydroxy-3-octadecanoyloxyoxolan-2-yl]-2-octadecanoyloxyethyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCCCCCCCCCCCC IJCWFDPJFXGQBN-RYNSOKOISA-N 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229940096529 carboxypolymethylene Drugs 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000000490 cosmetic additive Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000000385 dialysis solution Substances 0.000 description 1
- 229960002380 dibutyl phthalate Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 108010042224 enterocin L50A Proteins 0.000 description 1
- 108010042208 enterocin L50B Proteins 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000021121 fermented vegetables Nutrition 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 238000009920 food preservation Methods 0.000 description 1
- 235000019249 food preservative Nutrition 0.000 description 1
- 239000005452 food preservative Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 235000010494 karaya gum Nutrition 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 229960000826 meclocycline Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000004531 microgranule Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229940094335 peg-200 dilaurate Drugs 0.000 description 1
- 239000013520 petroleum-based product Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 229940079827 sodium hydrogen sulfite Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 229940001482 sodium sulfite Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 235000011071 sorbitan monopalmitate Nutrition 0.000 description 1
- 239000001570 sorbitan monopalmitate Substances 0.000 description 1
- 229940031953 sorbitan monopalmitate Drugs 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 235000011078 sorbitan tristearate Nutrition 0.000 description 1
- 239000001589 sorbitan tristearate Substances 0.000 description 1
- 229960004129 sorbitan tristearate Drugs 0.000 description 1
- 239000012177 spermaceti Substances 0.000 description 1
- 229940084106 spermaceti Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 231100000211 teratogenicity Toxicity 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
Definitions
- the present invention relates to novel use of bacteriocin derived from Enterococcus faecalis SL-5. More particularly, the present invention relates to a composition for preventing and treating acne comprising a polypeptide of SEQ ID NO: 1 or SEQ ID NO: 2, which is a bacteriocin derived from Enterococcus faecalis SL-5. Also, it relates to use of the bacteriocin for the manufacture of an agent for preventing or treating acne, and a method for preventing or treating acne comprising administering or applying the bacteriocin to subject in need thereof.
- acne is known to develop as a result of inflammatory response caused by irritations due to free fatty acids generated by the lipase of the anaerobic bacterium Propionibacterium acnes which inhabits the skin and various other low- molecular- weight substances. Oral or topical treatments are used to treat acne.
- Examples include a sebum secretion inhibitor using antiandrogen, a treatment utilizing the anti-inflammatory actions of steroids and non-steroidal analgesic inflammation drugs, an antibacterial agent or a keratin exfoliator such as resorcinol, sul&r, salicylic acid, benzoyl peroxide, retinoic acid or isotretinoin, an antibiotic such as tetracycline, erythromycin, meclocycline, etc. to inhibit the activity of Propionibacterium acnes, or the like. Recently, azelaic acid is also used to treat acne.
- an antibacterial agent or a keratin exfoliator such as resorcinol, sul&r, salicylic acid, benzoyl peroxide, retinoic acid or isotretinoin
- an antibiotic such as tetracycline, erythromycin, meclocycline, etc. to inhibit the activity of Propionibacterium acnes, or the like.
- the hormonal treatments are reportedly associated with side effects svch as the inhibition of epidermal growth and the abuse of hormones.
- the keratin exfoliators svch as retinoic acid, benzoyl peroxide, etc. are associated with skin irritation and contact dermatitis due to the exfoliation of the horny layer.
- the antibiotics svch as tetracycline are associated with the problems of antibiotic-resistant bacteria and hyperphotosensitivity. Especially, isotretinoin is known to be highly likely to cause teratogenicity.
- Lactic acid bacteria are widely distributed in the nature and produce lactic acid by fermenting carbohydrate anaerobically. Because this bacterium inhibits the growth of spoilage microorganisms which proliferate well in neutral to alkaline environments, it has been historically used to preserve food in the East and the West. Particularly, it has been used in processing of milk, dairy products, meats, fermented vegetables, and salted fish. Through various organic acids which are metabolic products of the lactic acid bacteria, these bacteria lower pH and improve food preservation. This is because the organic acids such as lactic acid and acetic acid have bactericidal effect on most microorganisms. In addition to the organic acids, hydrogen peroxide and bacteriocins produced by the bacteria are related with preservability.
- Bacteriocins are proteins or proteinaceous toxins produced by bacteria to inhibit the growth of phylogenically similar or closely related bacterial strains. They are natural antibacterial proteins distinguished from other antibiotics in that they exhibit narrow antibacterial spectrum and are synthesized directly from the genes of the corresponding bacteria. Bacteriocin is easily found in various fermented foods and is produced by lactic acid bacteria which are taken in through daily diets. Because they are composed of proteins, differently from other antibiotics, they are broken down by proteases in the digestive organ as soon as they are taken in. Because of the non- toxicity and non-residence resulting therefrom, bacteriocins are highly valued as preservative or microorganism control agent for fermented foods.
- Nisin which is the best known bacteriocin produced by lactic acid bacteria, has been long used as a food preservative because of its wide antibacterial spectrum.
- FDA US. Food and Drug Administration
- nisin as a GRAS (generally recognized as safe) food additive.
- an objection of the present invention is to provide novel use of a polypeptide of SEQ ID NO: 1 or SEQ ID NO: 2.
- the present invention provides a composition for preventing and treating acne comprising a polypeptide having an amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 2 as an effective component.
- the present invention provides an antibiotic composition against Propionibacterium acnes comprising a polypeptide having an amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 2 as an effective component.
- the present invention provides a method for inhibiting growth of Propionibacterium acnes comprising the step of applying a polypeptide having an amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 2.
- the present invention provides an use of a polypeptide having the amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 2 for the manufacture of an agent for treating acne.
- the present invention provides a method for preventing or treating acne comprising administering or applying a polypeptide having the amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 2 with an effective amount to subject in need thereof.
- the present invention provides an use of a polypeptide having the amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 2 for the manufacture of an antibacterial agent for Propionibacterium acnes.
- the present invention provides a method for removing Propionibacterium acnes comprising administering or applying a polypeptide having the amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 2 with an effective amount to subject in need thereof.
- the present invention provides a polypeptide of SEQ ID NO: 1 or SEQ
- inventive polypeptide can inhibit growth of Propionibacterium acnes by having excellent anti- bacterial activity against them inducing acne. Accordingly, the inventive polypeptide can be effectively used in preventing, treating and improving acne.
- FIG. 1 shows the antibacterial activity of Enterococcus faecalis SL-5 (A: Propioni- bacterium acnes ATCC 29399, B: Bacillus subtilis KFRI 179, C: Bacillus cereus KCTC 3624; D: Staphylococcus aureus KCTC 1927); and
- FIG. 2 shows the result of partial purification of the inventive bacteriocin (A) and the antibacterial activity of a gel replicated therefrom against Propionibacterium acnes (B).
- the inventive composition is characterized in that it comprises a polypeptide having the amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 2 as an effective component.
- the inventors of the present invention confirmed an antibiotic activity spectrum of Enterococcus faecalis SL-5. Also, the present invention confirmed that it has antibacterial activity against Propionibacterium acnes inducing acne.
- the inventors of the present invention confirmed N-terminal sequences by partial-purifying materials having antibacterial activity, thereby separating peptides having antibacterial activity by PCR. Accordingly, the inventors of the present invention confirmed a polypeptide having the amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 2.
- inventive polypeptide can be chemically synthesized according to any technique known in the art (Creighton, Proteins: Strictures and Molecular Principles, W.H. Freeman and Co., NY, 1983). Namely, the inventive polypeptide can be prepared by conventional step-wise liquid or solid phase synthesis, fragment condensation, F-MOC or T-BOC chemistry (Chemical Approaches to the Synthesis of Peptides and Proteins, Williams et al., Eds., CRC Press, Boca Raton Florida, 1997; A Practical Approach, Atherton & Sheppard, Eds., IRL Press, Oxford, England, 1989).
- the polypeptide according to the present invention can be prepared by a genetic engineering method.
- a DNA sequence encoding the polypeptide is first constructed according to any conventional method.
- the DNA sequence may synthesized by performing PCR using suitable primers.
- the DNA sequence may also be synthesized by a standard method known in the art, for example using an automatic DNA synthesizer (commercially available from Biosearch or Applied Biosystems).
- the constructed DNA sequence is inserted into a vector comprising at least one expression control sequence(ex: promoter, enhancer) that is operatively linked to the DNA sequence so as to control the expression of the DNA molecule, and host cells are transformed with the resulting recombinant expression vector.
- the transformed cells are cultured in a medium and condition suitable to express the DNA sequence, and a substantially pure polypeptide encoded by the DNA sequence is collected from the culture medium.
- the collection of the pure polypeptide may be performed using a method known in the art, for example, chromatography.
- substantially pure polypeptide means the inventive polypeptide that does not substantially contain any other proteins derived from host cells.
- the present invention provides an antibiotic composition against Propi- onibacterium acnes comprising a polypeptide having an amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 2 as an effective component because the polypeptides inhibit growth of Propionibacterium acnes.
- inventive composition for preventing and treating acne comprising a polypeptide having an amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 2 as an effective component, may be provided in types of prodtct.
- the product may be cosmetics or medicines.
- the inventive composition may comprise at least one pharmaceutically acceptable carrier, excipient or diluent additionally.
- a pharmaceutically acceptable carrier for example, carriers for the parenteral preparations may be included additionally.
- the carriers for the parenteral preparations may comprise water, suitable oil, saline, aqueous glucose and glycol, and stabilizers and preservatives additionally.
- the examples of the stabilizers may be antioxidant such as sodium hydrogen sulfite, sodium sulfite, and ascorbic acid.
- the examples of the preservatives may be benzalkonium chloride, methyl- or propyl-paraben, and chlorobutanol.
- the list of pharmaceutically acceptable carriers are disclosed in Remington's Pharmaceutical Sciences, 19th ed., Mack Publishing Company, Easton, PA, 1995.
- a medicine comprising the composition of the present invention may be administered to mammals including human beings by any methods.
- the composition of the present invention may be administered by intracutaneous administration.
- the term 'intracutaneous administration' as used herein means that the composition of the present invention is administrated in cell or skin, thereby transmitting active ingredients.
- the composition of the present invention may be formulated into a formulation for injection, which is administered by lightly pricking the skin with 30 gauge injection needle. Otherwise, such formulations for injection may be applied directly onto the skin.
- inventive pharmaceutical composition may be formulated according to the administration route such as the above.
- parenteral preparations they can be formulated in the form of injections, creams, lotions, external ointments, oils, moisturizers, gels, aerosols, and nasal inhalers by any method known in the art. These preparations are described in the following formulary known to all pharmaceutical chemists: Remington's Pharmaceutical Science, 15th Edition, 193, Mack Publishing Company, Easton, Pennsylvania 18042, Chapter 87: Blaug, Seymour.
- the total effective amount of the inventive peptide can be administered to a subject as a single dose, or can be administered using a fractionated treatment protocol, in which the multiple doses are administered over a more prolonged period of time.
- the content of the active ingredient in the inventive composition may be varied depending on the severity of disease.
- the effective dose of the polypeptide may be determined depending on many factors, such as the age, body weight, health condition, sex, disease severity, diet and excretion of a subject in need of treatment, as well as administration time and administration route. In view of these factors, any person skilled in the art may determine an effective dose.
- the effective dose is 0.001 ⁇ g/kg(body weight) to 10 mg/kg(body weight).
- the inventive polypeptide may be prepared into any formulation adequate for topical application using a method known in the art by additionally including a cosmetically and/or dermatologically acceptable excipient.
- the inventive cosmetic composition may be prepared into solution, gel, solid, emulsion, suspension, microemulsion, microcapsule, microgranule, ionic and/or non-ionic follicular dispersion, cream, lotion, powder, ointment, spray or stick.
- the cosmetically and/or dermatologically acceptable excipient may comprise a skin softener, an emulsifier, a thickener and a solvent.
- the skin softener is used to soften, soothe, coat, smoothen or moisturize the skin.
- the skin softener may be any one known in the art.
- it may be a petroleum based product, a fatty acid ester, an alkyl ethoxylate, a fatty acid ester ethoxylate, a fatty alcohol, a polysiloxane or a mixture thereof.
- skin softeners such as propylene glycol, butylene glycol, glycerin, tri- ethylene glycol, spermaceti, wax, fatty acid, fatty alcohol ether, glyceride, acet- oglyceride, ethoxylated glyceride, polyhydroxy alcohols and other fatty acid esters, lanolin and its derivatives are included.
- the emulsifier serves to make the water phase and the oil phase of the inventive cosmetic composition miscible with each other.
- one or more of the emulsifier may be included.
- the emulsifier may be non-ionic, anionic or cationic.
- the type of the emulsifier may be determined depending on whether the emulsion is water-in-oil type or oil-in- water type.
- Suitable emulsifier examples include, although not limited thereto, sorbitan trioleate, sorbitan tristearate, glycerol monooleate, glycerol monostearate, glycerol monolaurate, sorbitan sesqiioleate, sorbitan monooleate, sorbitan monostearate, polyoxyethylene stearyl ether, poly- oxyethylene sorbitol beeswax derivative, PEG 200 dilaurate, PEG 200 monostearate, PEG 400 dioleate, sorbitan monopalmitate, polyoxyethylene monostearate, polyoxyethylene sorbitan monostearate, and the like.
- the thickener may include crosslinked carboxypolymethylene polymer, ethyl cellulose, polyethylene glycol, gum tragacanth, gum karaya, xanthan gum, bentonite, hydroxyethyl cellulose and hydroxypropyl cellulose.
- the solvent may include purified water, alcohol or a mixture of purified water and alcohol.
- a preservative such as /?-hydroxybenzoate ester, an antioxidant sirh as butyl- hydroxytoluene, ascorbic acid and its derivative, and tocopherol and its derivative
- a wetting agent such as glycerol, sorbitol, 2-pyrrolidone-5-carboxylate, dibutylphthalate, gelatin and polyethylene glycol
- a pH buffering agent such as acetate, phosphate, citrate, triethanolamine and carbonate
- a wax sirh as beeswax and paraffin
- a vis- cosifier an activity enhancer, a colorant, and a fragrance.
- the present invention provides a method for inhibiting growth of Propi- onibacterium acnes comprising the step of applying a polypeptide having an amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 2 because the polypeptide inhibit growth of Propionibacterium acnes.
- the present invention provides an use of a polypeptide having the amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 2 for the manufacture of an agent for treating acne. Also, the present invention provides an use of a polypeptide having the amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 2 for the manufacture of an antibacterial agent for Propionibacterium acnes.
- the present invention provides a method for preventing or treating acne comprising administering or applying a polypeptide having the amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 2 with an effective amount to subject in need thereof. Also, the present invention provides a method for removing Propionibacterium acnes comprising administering or applying a polypeptide having the amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 2 with an effective amount to subject in need thereof.
- the term "effective amount” refers to an amount effective in preventing and treating acne and removing Propionibacterium acnes in subject in need of the inventive polypeptide.
- the term "subject” means mammals, and particularly animals including human beings.
- the subject may be human beings in need of preventing and treating acne and removing Propionibacterium acnes
- inventive polypeptide may be administered until the desired effect of the above effects.
- inventive polypeptide may be administered by various oral or parenteral routes according to any method known in the art
- Example 1 Cell culturing and confirmation of antibacterial spectrum
- No. AY692453 was inoculated to a liquid MRS medium, and cultured for about 16 hours at 37 0 C, under nitrogen-replaced anaerobic condition.
- Propionibacterium acnes (ATCC 29399) was cultured in RCM broth (reinforced clostridial medium broth; Merck, Darmstadt, Germany), and Bacillus subtilis (KFRI 179), Bacillus cereus (KCTC 3624), Staphylococcus aureus (KCTC 1972), E. coli 0157, Listeria monocytogenes, Salmonella paratyphi A and Shigella flexneri were cultured in BHI broth (brain heart infusion broth), at 37 0 C for about 16 hours.
- the culture supernatant was serially diluted two-folds using oxygen-free water (42.3 mM Na 2 HPO 4 , 33.1 mM KH 2 PO 4 , 0.05% (v/v) Tween 80, 3.2 mM L- cystein-HCl, pH 7.0). 10 j ⁇ of the diluted extract was dropped on an MRS agar plate containing test bacteria and culturing was carried out at 37 0 C. Antibacterial activity was identified by determining whether a clear zone was formed around the dropping position.
- Enterococcus faecalis SL-5 had antibacterial activity against the Gram-positive bacteria Bacillus cereus KCTC 3624, Bacillus subtilis KFRI 179, Listeria monocytogenes, Propionibacterium acnes ATCC 29399 and Staphylococcus aureus KCTC 1927, but no antibacterial activity against E. coli 0157, Shigella flexneri and Salmonella paratyphi A.
- the 5 kDa protein was transferred to a PVDF (polyvinylidene fluoride) membrane. After cutting out the protein band showing antibacterial activity from the PVDF membrane, the first ten N-terminal amino acid residues were determined using an automatic protein sequence analyzer.
- PVDF polyvinylidene fluoride
- the bacteriocin of Enterococcus faecalis SL-5 is identical to or has substantial identity to enterocin MRlO or L50 however, antibacterial activity of the bacterocin against acne-causing Propionibacterium acnes was newly discovered by the present inventor.
- the present invention provides Enterococcus faecalis SL-5 and a polypeptide of SEQ ID NO: 1 or SEQ ID NO: 2 derived from it, which shows excellent antibacterial activity against Propionibacterium acnes inducing acne. Accordingly, the inventive polypeptide and Enterococcus faecalis SL-5 can inhibit growth of Propionibacterium acnes by having excellent antibacterial activity against them inducing acne. Accordingly, the inventive polypeptide and Enterococcus faecalis SL-5 can be effectively used in preventing, treating and improving acne.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Birds (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Cosmetics (AREA)
Abstract
The present invention relates to novel use of bacteriocin derived from Enterococcus faecalis SL-5. More particularly, the present invention relates to a composition for preventing and treating acne comprising a polypeptide of SEQ ID NO: 1 or SEQ ID NO: 2, which is a bacteriocin derived from Enterococcus faecalis SL-5. Also, it relates to use of the bacteriocin for the manufacture of an agent for preventing or treating acne, and a method for preventing or treating acne comprising administering or applying the bacteriocin to subject in need thereof. The present invention provides a polypeptide of SEQ ID NO: 1 or SEQ ID NO: 2 derived from Enterococcus
faecalis SL-5, which shows excellent antibacterial activity against Propionibacterium acnes inducing acne. The inventive polypeptide can inhibit growth of Propionibacterium acnes by having excellent antibacterial activity against them inducing acne. Accordingly, the inventive polypeptide can be effectively used in preventing, treating and improving acne.
Description
Description
NOVEL USE OF BACTERIOCIN DERIVED FROM EN- TEROCOCCUS FAECALIS SL-5
Technical Field
[1] The present invention relates to novel use of bacteriocin derived from Enterococcus faecalis SL-5. More particularly, the present invention relates to a composition for preventing and treating acne comprising a polypeptide of SEQ ID NO: 1 or SEQ ID NO: 2, which is a bacteriocin derived from Enterococcus faecalis SL-5. Also, it relates to use of the bacteriocin for the manufacture of an agent for preventing or treating acne, and a method for preventing or treating acne comprising administering or applying the bacteriocin to subject in need thereof.
[2]
Background Art
[3] In general, acne is known to develop as a result of inflammatory response caused by irritations due to free fatty acids generated by the lipase of the anaerobic bacterium Propionibacterium acnes which inhabits the skin and various other low- molecular- weight substances. Oral or topical treatments are used to treat acne. Examples include a sebum secretion inhibitor using antiandrogen, a treatment utilizing the anti-inflammatory actions of steroids and non-steroidal analgesic inflammation drugs, an antibacterial agent or a keratin exfoliator such as resorcinol, sul&r, salicylic acid, benzoyl peroxide, retinoic acid or isotretinoin, an antibiotic such as tetracycline, erythromycin, meclocycline, etc. to inhibit the activity of Propionibacterium acnes, or the like. Recently, azelaic acid is also used to treat acne.
[4] Although the aforesaid treatments are effective in treating acne to some extent, they have the following problems. The hormonal treatments are reportedly associated with side effects svch as the inhibition of epidermal growth and the abuse of hormones. The keratin exfoliators svch as retinoic acid, benzoyl peroxide, etc. are associated with skin irritation and contact dermatitis due to the exfoliation of the horny layer. The antibiotics svch as tetracycline are associated with the problems of antibiotic-resistant bacteria and hyperphotosensitivity. Especially, isotretinoin is known to be highly likely to cause teratogenicity.
[5] Accordingly, there are needs for the development of an acne treatment which provides superior therapeutic effect while being safe for human body.
[6] Lactic acid bacteria are widely distributed in the nature and produce lactic acid by
fermenting carbohydrate anaerobically. Because this bacterium inhibits the growth of spoilage microorganisms which proliferate well in neutral to alkaline environments, it has been historically used to preserve food in the East and the West. Particularly, it has been used in processing of milk, dairy products, meats, fermented vegetables, and salted fish. Through various organic acids which are metabolic products of the lactic acid bacteria, these bacteria lower pH and improve food preservation. This is because the organic acids such as lactic acid and acetic acid have bactericidal effect on most microorganisms. In addition to the organic acids, hydrogen peroxide and bacteriocins produced by the bacteria are related with preservability.
[7] Bacteriocins are proteins or proteinaceous toxins produced by bacteria to inhibit the growth of phylogenically similar or closely related bacterial strains. They are natural antibacterial proteins distinguished from other antibiotics in that they exhibit narrow antibacterial spectrum and are synthesized directly from the genes of the corresponding bacteria. Bacteriocin is easily found in various fermented foods and is produced by lactic acid bacteria which are taken in through daily diets. Because they are composed of proteins, differently from other antibiotics, they are broken down by proteases in the digestive organ as soon as they are taken in. Because of the non- toxicity and non-residence resulting therefrom, bacteriocins are highly valued as preservative or microorganism control agent for fermented foods. Nisin, which is the best known bacteriocin produced by lactic acid bacteria, has been long used as a food preservative because of its wide antibacterial spectrum. In 1988, the US. Food and Drug Administration (FDA) approved nisin as a GRAS (generally recognized as safe) food additive.
[8]
Disclosure of Invention Technical Problem
[9] Therefore, the inventors of the present invention have conducted intensive studies to search antibiotic activity of Enterococcus faecalis SL-5. Finally, we have found that it has excellent antibacterial activity against Propionibacterium acnes inducing acne and confirmed that a polypeptide of SEQ ID NO: 1 or SEQ ID NO: 2 has excellent antibacterial activity against Propionibacterium acnes. Therefore, we have developed a composition for preventing and treating acne comprising a polypeptide of SEQ ID NO: 1 or SEQ ID NO: 2 as an effective component, thereby completing the present invention.
[10] Accordingly, an objection of the present invention is to provide novel use of a polypeptide of SEQ ID NO: 1 or SEQ ID NO: 2. [H]
Technical Solution
[12] To achieve the above object, the present invention provides a composition for preventing and treating acne comprising a polypeptide having an amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 2 as an effective component.
[13] In order to accomplish another object, the present invention provides an antibiotic composition against Propionibacterium acnes comprising a polypeptide having an amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 2 as an effective component.
[14] In order to accomplish another object, the present invention provides a method for inhibiting growth of Propionibacterium acnes comprising the step of applying a polypeptide having an amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 2.
[15] In order to accomplish another object, the present invention provides an use of a polypeptide having the amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 2 for the manufacture of an agent for treating acne.
[16] In order to accomplish another object, the present invention provides a method for preventing or treating acne comprising administering or applying a polypeptide having the amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 2 with an effective amount to subject in need thereof.
[17] In order to accomplish another object, the present invention provides an use of a polypeptide having the amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 2 for the manufacture of an antibacterial agent for Propionibacterium acnes.
[18] In order to accomplish another object, the present invention provides a method for removing Propionibacterium acnes comprising administering or applying a polypeptide having the amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 2 with an effective amount to subject in need thereof.
Advantageous Effects
[19] Accordingly, the present invention provides a polypeptide of SEQ ID NO: 1 or SEQ
ID NO: 2 derived from Enterococcus faecalis SL-5, which shows excellent antibacterial activity against Propionibacterium acnes inducing acne. The inventive polypeptide can inhibit growth of Propionibacterium acnes by having excellent anti-
bacterial activity against them inducing acne. Accordingly, the inventive polypeptide can be effectively used in preventing, treating and improving acne.
[20]
Brief Description of the Drawings
[21] The above and other objects, features and other advantages of the present invention will be more clearly understood from the following detailed description taken in conjunction with the accompanying drawings, in which:
[22] Fig. 1 shows the antibacterial activity of Enterococcus faecalis SL-5 (A: Propioni- bacterium acnes ATCC 29399, B: Bacillus subtilis KFRI 179, C: Bacillus cereus KCTC 3624; D: Staphylococcus aureus KCTC 1927); and
[23] Fig. 2 shows the result of partial purification of the inventive bacteriocin (A) and the antibacterial activity of a gel replicated therefrom against Propionibacterium acnes (B).
[24]
Best Mode for Carrying Out the Invention
[25] Hereinafter, the present invention will be described in detail.
[26] The inventive composition is characterized in that it comprises a polypeptide having the amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 2 as an effective component.
[27] According to an embodiment of the present invention, the inventors of the present invention confirmed an antibiotic activity spectrum of Enterococcus faecalis SL-5. Also, the present invention confirmed that it has antibacterial activity against Propionibacterium acnes inducing acne.
[28] Additionally, according to another embodiment of the present invention, the inventors of the present invention confirmed N-terminal sequences by partial-purifying materials having antibacterial activity, thereby separating peptides having antibacterial activity by PCR. Accordingly, the inventors of the present invention confirmed a polypeptide having the amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 2.
[29] The inventive polypeptide can be chemically synthesized according to any technique known in the art (Creighton, Proteins: Strictures and Molecular Principles, W.H. Freeman and Co., NY, 1983). Namely, the inventive polypeptide can be prepared by conventional step-wise liquid or solid phase synthesis, fragment condensation, F-MOC or T-BOC chemistry (Chemical Approaches to the Synthesis of Peptides and Proteins,
Williams et al., Eds., CRC Press, Boca Raton Florida, 1997; A Practical Approach, Atherton & Sheppard, Eds., IRL Press, Oxford, England, 1989).
[30] Alternatively, the polypeptide according to the present invention can be prepared by a genetic engineering method. A DNA sequence encoding the polypeptide is first constructed according to any conventional method. The DNA sequence may synthesized by performing PCR using suitable primers. Alternatively, the DNA sequence may also be synthesized by a standard method known in the art, for example using an automatic DNA synthesizer (commercially available from Biosearch or Applied Biosystems). The constructed DNA sequence is inserted into a vector comprising at least one expression control sequence(ex: promoter, enhancer) that is operatively linked to the DNA sequence so as to control the expression of the DNA molecule, and host cells are transformed with the resulting recombinant expression vector. The transformed cells are cultured in a medium and condition suitable to express the DNA sequence, and a substantially pure polypeptide encoded by the DNA sequence is collected from the culture medium. The collection of the pure polypeptide may be performed using a method known in the art, for example, chromatography. In this regard, the term "substantially pure polypeptide" means the inventive polypeptide that does not substantially contain any other proteins derived from host cells. For the genetic engineering method for synthesizing the inventive polypeptide, the reader may refer to the following literatures: Maniatis et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory 1982; Sambrook et al., supra; Gene Expression Technology, Method in Enzymology, Genetics and Molecular Biology, Method in En- zymology, Guthrie & Fink (eds.), Academic Press, San Diego, Calif. 1991; and Hitzeman et al., J. Biol. Chem., 255, 12073-12080 1990.
[31] Meanwhile, the present invention provides an antibiotic composition against Propi- onibacterium acnes comprising a polypeptide having an amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 2 as an effective component because the polypeptides inhibit growth of Propionibacterium acnes.
[32] Also, the inventive composition for preventing and treating acne comprising a polypeptide having an amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 2 as an effective component, may be provided in types of prodtct. The product may be cosmetics or medicines.
[33] In case of the medicine, the inventive composition may comprise at least one pharmaceutically acceptable carrier, excipient or diluent additionally. A pharmaceutically acceptable carrier, for example, carriers for the parenteral preparations may be
included additionally. The carriers for the parenteral preparations may comprise water, suitable oil, saline, aqueous glucose and glycol, and stabilizers and preservatives additionally. The examples of the stabilizers may be antioxidant such as sodium hydrogen sulfite, sodium sulfite, and ascorbic acid. The examples of the preservatives may be benzalkonium chloride, methyl- or propyl-paraben, and chlorobutanol. The list of pharmaceutically acceptable carriers are disclosed in Remington's Pharmaceutical Sciences, 19th ed., Mack Publishing Company, Easton, PA, 1995.
[34] A medicine comprising the composition of the present invention may be administered to mammals including human beings by any methods. Preferably, the composition of the present invention may be administered by intracutaneous administration. The term 'intracutaneous administration' as used herein means that the composition of the present invention is administrated in cell or skin, thereby transmitting active ingredients. For example, the composition of the present invention may be formulated into a formulation for injection, which is administered by lightly pricking the skin with 30 gauge injection needle. Otherwise, such formulations for injection may be applied directly onto the skin.
[35] The inventive pharmaceutical composition may be formulated according to the administration route such as the above. In case of the parenteral preparations, they can be formulated in the form of injections, creams, lotions, external ointments, oils, moisturizers, gels, aerosols, and nasal inhalers by any method known in the art. These preparations are described in the following formulary known to all pharmaceutical chemists: Remington's Pharmaceutical Science, 15th Edition, 193, Mack Publishing Company, Easton, Pennsylvania 18042, Chapter 87: Blaug, Seymour.
[36] The total effective amount of the inventive peptide can be administered to a subject as a single dose, or can be administered using a fractionated treatment protocol, in which the multiple doses are administered over a more prolonged period of time. The content of the active ingredient in the inventive composition may be varied depending on the severity of disease. The effective dose of the polypeptide may be determined depending on many factors, such as the age, body weight, health condition, sex, disease severity, diet and excretion of a subject in need of treatment, as well as administration time and administration route. In view of these factors, any person skilled in the art may determine an effective dose. Preferably, the effective dose is 0.001 μg/kg(body weight) to 10 mg/kg(body weight). No particular limitation is imposed on the formulation, administration route and administration mode, as long as a product comprising the inventive composition shows the effects of the present invention.
[37] And, in case of the cosmetics, the inventive polypeptide may be prepared into any formulation adequate for topical application using a method known in the art by additionally including a cosmetically and/or dermatologically acceptable excipient. For example, although not limited thereto, the inventive cosmetic composition may be prepared into solution, gel, solid, emulsion, suspension, microemulsion, microcapsule, microgranule, ionic and/or non-ionic follicular dispersion, cream, lotion, powder, ointment, spray or stick.
[38] The cosmetically and/or dermatologically acceptable excipient may comprise a skin softener, an emulsifier, a thickener and a solvent.
[39] The skin softener is used to soften, soothe, coat, smoothen or moisturize the skin. In the present invention, the skin softener may be any one known in the art. For example, it may be a petroleum based product, a fatty acid ester, an alkyl ethoxylate, a fatty acid ester ethoxylate, a fatty alcohol, a polysiloxane or a mixture thereof. Further, commonly used skin softeners such as propylene glycol, butylene glycol, glycerin, tri- ethylene glycol, spermaceti, wax, fatty acid, fatty alcohol ether, glyceride, acet- oglyceride, ethoxylated glyceride, polyhydroxy alcohols and other fatty acid esters, lanolin and its derivatives are included.
[40] The emulsifier serves to make the water phase and the oil phase of the inventive cosmetic composition miscible with each other. In the present invention, one or more of the emulsifier may be included. The emulsifier may be non-ionic, anionic or cationic. The type of the emulsifier may be determined depending on whether the emulsion is water-in-oil type or oil-in- water type. Examples of the suitable emulsifier include, although not limited thereto, sorbitan trioleate, sorbitan tristearate, glycerol monooleate, glycerol monostearate, glycerol monolaurate, sorbitan sesqiioleate, sorbitan monooleate, sorbitan monostearate, polyoxyethylene stearyl ether, poly- oxyethylene sorbitol beeswax derivative, PEG 200 dilaurate, PEG 200 monostearate, PEG 400 dioleate, sorbitan monopalmitate, polyoxyethylene monostearate, polyoxyethylene sorbitan monostearate, and the like.
[41] The thickener may include crosslinked carboxypolymethylene polymer, ethyl cellulose, polyethylene glycol, gum tragacanth, gum karaya, xanthan gum, bentonite, hydroxyethyl cellulose and hydroxypropyl cellulose.
[42] The solvent may include purified water, alcohol or a mixture of purified water and alcohol.
[43] In addition, other commonly used cosmetic additives including, although not limited thereto, a preservative such as /?-hydroxybenzoate ester, an antioxidant sirh as butyl-
hydroxytoluene, ascorbic acid and its derivative, and tocopherol and its derivative, a wetting agent such as glycerol, sorbitol, 2-pyrrolidone-5-carboxylate, dibutylphthalate, gelatin and polyethylene glycol, a pH buffering agent such as acetate, phosphate, citrate, triethanolamine and carbonate, a wax sirh as beeswax and paraffin, a vis- cosifier, an activity enhancer, a colorant, and a fragrance.
[44] Meanwhile, the present invention provides a method for inhibiting growth of Propi- onibacterium acnes comprising the step of applying a polypeptide having an amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 2 because the polypeptide inhibit growth of Propionibacterium acnes.
[45] Moreover, the present invention provides an use of a polypeptide having the amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 2 for the manufacture of an agent for treating acne. Also, the present invention provides an use of a polypeptide having the amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 2 for the manufacture of an antibacterial agent for Propionibacterium acnes.
[46] The present invention provides a method for preventing or treating acne comprising administering or applying a polypeptide having the amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 2 with an effective amount to subject in need thereof. Also, the present invention provides a method for removing Propionibacterium acnes comprising administering or applying a polypeptide having the amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 2 with an effective amount to subject in need thereof.
[47] The polypeptide having the amino acid sequence represented by SEQ ID NO: 1 or
SEQ ID NO: 2 and the effects thereof are described above.
[48] As used herein, the term "effective amount" refers to an amount effective in preventing and treating acne and removing Propionibacterium acnes in subject in need of the inventive polypeptide.
[49] As used herein, the term "subject" means mammals, and particularly animals including human beings. The subject may be human beings in need of preventing and treating acne and removing Propionibacterium acnes
[50] The inventive polypeptide may be administered until the desired effect of the above effects. The inventive polypeptide may be administered by various oral or parenteral routes according to any method known in the art
[51]
Mode for the Invention
[52] Hereinafter, the present invention will be described in detail by examples.
[53] It is to be understood, however, that these examples are for illustrative purpose only and are not construed to limit the scope of the present invention.
[54]
[55] Example 1: Cell culturing and confirmation of antibacterial spectrum
[56] 1-1. Cell culturing
[57] Enterococcus faecalis SL-5 (16s rRNA thereof was registered as GenBank Accession
No. AY692453) was inoculated to a liquid MRS medium, and cultured for about 16 hours at 37 0C, under nitrogen-replaced anaerobic condition. Propionibacterium acnes (ATCC 29399) was cultured in RCM broth (reinforced clostridial medium broth; Merck, Darmstadt, Germany), and Bacillus subtilis (KFRI 179), Bacillus cereus (KCTC 3624), Staphylococcus aureus (KCTC 1972), E. coli 0157, Listeria monocytogenes, Salmonella paratyphi A and Shigella flexneri were cultured in BHI broth (brain heart infusion broth), at 37 0C for about 16 hours.
[58]
[59] 1-2. Confirmation of antibacterial activity spectrum of Enterococcus faecalis SL-5
[60] After removing the cellular elements from the culture medium of E. faecalis SL-5 by centrifugation (9,940 x g, 15 minutes, 4 0C), the resultant supernatant of the culture medium was further filtered (membrane pore size = 0.45 /M) to completely remove the remaining cellular elements. Thus the obtained supernatant portion was named "culture supernatant". Antibacterial activity of the culture supernatant was measured by the "spot-on-the-lawn" method (Van Reenen et al., 2006, Appl. Environ. Microbiol. 72: 7644-7651). The culture supernatant was serially diluted two-folds using oxygen-free water (42.3 mM Na2HPO4, 33.1 mM KH2PO4, 0.05% (v/v) Tween 80, 3.2 mM L- cystein-HCl, pH 7.0). 10 jΛ of the diluted extract was dropped on an MRS agar plate containing test bacteria and culturing was carried out at 37 0C. Antibacterial activity was identified by determining whether a clear zone was formed around the dropping position.
[61] As seen from Fig. 1 and Table 1, Enterococcus faecalis SL-5 had antibacterial activity against the Gram-positive bacteria Bacillus cereus KCTC 3624, Bacillus subtilis KFRI 179, Listeria monocytogenes, Propionibacterium acnes ATCC 29399 and Staphylococcus aureus KCTC 1927, but no antibacterial activity against E. coli 0157, Shigella flexneri and Salmonella paratyphi A.
[62] Table 1
[Table 1] [Table ]
[63] Example 2: Identification of antibacterial substance
[64] 2- 1. Partial purification of antibacterial substance
[65] Partial purification was carried out in order to identify the substance that exhibit antibacterial activity. Enterococcus faecalis SL-5 was inoculated in 100 rnL of MRS medium. After culturing at 37 0C for 16 hours and inoculating in 2 L of fresh MRS medium, Enterococcus faecalis SL-5 was cultivated for 8 hours at 37 0C to prepare a culture supernatant as in Example 1.
[66] For fractionation of the culture supernatant, ammonium sulfate was slowly added to a final concentration of 70%. After dissolving, centri&gation (20,000 x g/ 30 minutes/ 4 0C) was carried out to obtain a precipitate. The precipitate was dissolved in a standard buffer solution (50 mM Tris-HCl, pH 7.0) to a final volume of 70 mL. Then, dialysis was carried out against the same buffer with buffer exchange for a total of three changes over 48 hour period, in order to remove the salts included in the solution, using dialysis tubing (MW cut-off = 500 dalton). Ultrafiltration (MW cut-off = 3,000 dalton) was carried out to concentrate the dialysis solution, and 8 mL of the concentrate (7 mg/mL) was fractionated using a CM Sepharose™ Fast Flow column (GE Healthcare), which is a type of liquid chromatography column. Fractionation was carried out with NaCl concentration gradients from 0 M to 1 M. Antibacterial activity against Propionibacterium acnes was detected at around 0.5 M NaCl. Of the fractions having antibacterial activity, the fraction with the highest activity was analyzed through 16% SDS-tricine gel electrophoresis. As seen in Fig. 2A, most of the proteins
were distributed near 5 kDa.
[67]
[68] 2-2. Identification of antibacterial active substance
[69] In order to confirm whether the protein with a size of about 5 kDa had antibacterial activity against Propionibacterium acnes, activity staining test was carried out as in Example 1-2, using a duplicate gel of the gel used in Fig. 2A.
[70] As seen in Fig. 2B, a clear zone was formed at the portion corresponding to the size of 5 kDa. Therefore, it was confirmed that the protein has antibacterial activity against Propionibacterium acnes.
[71]
[72] 2-3. Sequence analysis of antibacterial active substance
[73] In order to determine the amino acid sequence of the protein identified in Example
2-2, the 5 kDa protein was transferred to a PVDF (polyvinylidene fluoride) membrane. After cutting out the protein band showing antibacterial activity from the PVDF membrane, the first ten N-terminal amino acid residues were determined using an automatic protein sequence analyzer.
[74] The N-terminal sequence of the protein was identified as Met-
GIy- Ala- Ile-Ala-Lys-Leu- VaI- Ala- Lys.
[75] Thus the determined amino acid sequence was compared with protein sequences held in the NCBI (National Center for Biotechnology Information) protein database, using BLAST (Basic Alignment Search Tool). 100% identity was confirmed with enterocin MRlOA and B (Martin-Platero et al., 2006, AppL Environ. Microbiol. , 72:4245-4249) and enterocin L50A (Cintas et al., 1998, J. Bacteriol. 180: 1988-1994), and 90% identity was confirmed with enterocin L50B (Cintas et al., 1998, J. Bacteriol. 180: 1988-1994). Because enterocin MRlOA and B are considered as variants of enterocin L50, PCR primers of SEQ ID NO: 6 (5'-ATGGGAGCAATCGCAAAATTAGTA-S') and SEQ ID NO: 7
(5'-TTAATGTCTTTTTAGCCATTTTTCAATTTGATCTATTGT-S') were synthesized based on the base sequence of enterocin L50, and PCR was carried out using the total DNA of Enterococcus faecalis SL-5 as template. A 287bp PCR product was obtained. The total base sequence (SEQ ID NO: 5) was determined based on the DNA base sequence of the PCR prodtct. Through alignment comparison of thus determined base sequence with enterocin MRlO and enterocin L50, 100% identity was confirmed with the open reading frame (ORF) of enterocin MRlO. Structurally, the gene of Enterococcus faecalis SL-5 has two ORFs in tandem, which were named as SEQ ID NO:
3 and SEQ ID NO: 4.
[76] To conclude, the bacteriocin of Enterococcus faecalis SL-5 according to the present invention is identical to or has substantial identity to enterocin MRlO or L50 however, antibacterial activity of the bacterocin against acne-causing Propionibacterium acnes was newly discovered by the present inventor.
[77]
Industrial Applicability
[78] As can be seen from the foregoing, the present invention provides Enterococcus faecalis SL-5 and a polypeptide of SEQ ID NO: 1 or SEQ ID NO: 2 derived from it, which shows excellent antibacterial activity against Propionibacterium acnes inducing acne. Accordingly, the inventive polypeptide and Enterococcus faecalis SL-5 can inhibit growth of Propionibacterium acnes by having excellent antibacterial activity against them inducing acne. Accordingly, the inventive polypeptide and Enterococcus faecalis SL-5 can be effectively used in preventing, treating and improving acne.
Claims
[1] A composition for preventing and treating acne comprising a polypeptide having an amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 2 as an effective component.
[2] An antibiotic composition against Propionibacterium acnes comprising a polypeptide having an amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 2 as an effective component.
[3] A prodict comprising the composition of claim 1.
[4] The product of claim 3, wherein the product is a cosmetic or medicine.
[5] A method for inhibiting growth of Propionibacterium acnes comprising the step of applying a polypeptide having an amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 2.
[6] Use of a polypeptide having the amino acid sequence represented by SEQ ID
NO: 1 or SEQ ID NO: 2 for the manufacture of an agent for treating acne.
[7] A method for preventing or treating acne comprising administering or applying a polypeptide having the amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 2 with an effective amount to subject in need thereof.
[8] Use of a polypeptide having the amino acid sequence represented by SEQ ID
NO: 1 or SEQ ID NO: 2 for the manufacture of an antibacterial agent for Propionibacterium acnes.
[9] A method for removing Propionibacterium acnes comprising administering or applying a polypeptide having the amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 2 with an effective amount to subject in need thereof.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020080080930A KR20100022309A (en) | 2008-08-19 | 2008-08-19 | Composition for preventing and treating acne comprising bacteriocin derived from enterococcus faecalis sl-5 |
| PCT/KR2008/005118 WO2010021424A1 (en) | 2008-08-19 | 2008-09-01 | Novel use of bacteriocin derived from enterococcus faecalis sl-5 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP2323683A1 true EP2323683A1 (en) | 2011-05-25 |
Family
ID=41707292
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP08793616A Withdrawn EP2323683A1 (en) | 2008-08-19 | 2008-09-01 | Novel use of bacteriocin derived from enterococcus faecalis sl-5 |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP2323683A1 (en) |
| JP (1) | JP2012500257A (en) |
| KR (1) | KR20100022309A (en) |
| WO (1) | WO2010021424A1 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101689033B1 (en) * | 2014-06-10 | 2016-12-22 | 경북대학교 산학협력단 | Bacteriophage that kills Propionibacterium acnes |
| KR101906798B1 (en) * | 2017-08-28 | 2018-10-11 | 주식회사 쎌바이오텍 | Antibacterial Lactopad composition |
| JP7266202B2 (en) * | 2018-02-19 | 2023-04-28 | 株式会社ファンケル | Cosmetics and anti-inflammatory agents |
| KR102053730B1 (en) * | 2018-08-21 | 2019-12-09 | 주식회사 아미코스메틱 | A novel enterococcus faecalis strain ami-1001 having probiotics activity, and uses thereof |
| WO2020096058A1 (en) * | 2018-11-09 | 2020-05-14 | 学校法人立命館 | Agent for controlling sebaceous glands |
-
2008
- 2008-08-19 KR KR1020080080930A patent/KR20100022309A/en not_active Application Discontinuation
- 2008-09-01 JP JP2011523724A patent/JP2012500257A/en active Pending
- 2008-09-01 WO PCT/KR2008/005118 patent/WO2010021424A1/en active Application Filing
- 2008-09-01 EP EP08793616A patent/EP2323683A1/en not_active Withdrawn
Non-Patent Citations (1)
| Title |
|---|
| See references of WO2010021424A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010021424A1 (en) | 2010-02-25 |
| JP2012500257A (en) | 2012-01-05 |
| KR20100022309A (en) | 2010-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11759414B2 (en) | Yeast-based masks for improved skin, hair and scalp health | |
| KR20190140063A (en) | Cosmetic composition for skin health and method of using the same | |
| US20140057850A1 (en) | Peptide for use in the treatment of skin conditions | |
| KR20170032689A (en) | Novel antimicrobial peptide derived from myxinidin peptide and uses thereof | |
| EP2323683A1 (en) | Novel use of bacteriocin derived from enterococcus faecalis sl-5 | |
| US6221847B1 (en) | Composition and method for treating bacterial infection | |
| JP4726109B2 (en) | External preparation for skin, method for preventing adhesion and proliferation of harmful skin microorganisms using the same | |
| WO2012026346A1 (en) | Cytoprotective agent | |
| CN114984063B (en) | Skin external composition and functional food composition | |
| KR20140090794A (en) | Composition for treating or preventing disease related to sebaceous gland comprising eggplant extract | |
| US20240115756A1 (en) | Biosurfactant Formulations for Use in Skincare and Wound Treatment | |
| US20100048476A1 (en) | Novel use of bacteriocin derived from enterococcus faecalis sl-5 | |
| KR101252468B1 (en) | Cosmetics composition for skin troubles | |
| KR100536522B1 (en) | Novel bacteriocin isolated from human skin and the use as therapeutic agent of an acne | |
| KR102001241B1 (en) | Composition for improving microbial flora containing extract of Coicis Semen | |
| KR20190050358A (en) | Composition for improving microbial flora containing extract of violae herba | |
| WO2023220508A1 (en) | Compositions comprising brevibacilla multifunctional fermentates and methods of use | |
| WO2019167177A1 (en) | Topical skin composition containing marine-derived yeast culture | |
| Wang | Further purification and characterization of jenseniin P, a bacteriocin produced by Propionibacterium jensenii B1264 | |
| WO2023150176A1 (en) | Expression of the human lekti gene from the chromosome of staphylococcus epidermidis | |
| KR20230154199A (en) | skin probiotics | |
| KR20190050346A (en) | Composition for improving microbial flora containing extract of puerariae flos | |
| KR20190050359A (en) | Composition for improving microbial flora containing extract of Lepidii seu Descurainiae semen | |
| KR20190050354A (en) | Composition for improving microbial flora containing extract of jujube | |
| KR20190050356A (en) | Composition for improving microbial flora containing extract of Perilla herba |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20100519 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR |
|
| AX | Request for extension of the european patent |
Extension state: AL BA MK RS |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
| 18W | Application withdrawn |
Effective date: 20110617 |